Document is current
Any future updates will be listed below
-
Authors
,
Oshima, Megumi https://orcid.org/0000-0002-4108-5229
Jun, Min
Ohkuma, Toshiaki
Toyama, Tadashi
Wada, Takashi
Cooper, Mark E.
Hadjadj, Samy
Hamet, Pavel
Harrap, Stephen
Mancia, Giuseppe
Marre, Michel
Williams, Bryan
Chalmers, John
Woodward, Mark
Perkovic, Vlado
-
Funding
Funding for this research was provided by:
the John Chalmers Clinical Research Fellowship of the George Institute
Servier
the Japan Society of Women Nephrologist
National Health and Medical Research Council
the Scientia Fellowship from UNSW Sydney
Japan Society for the Promotion of Science
- License Information
-
More Information
Article History
Received: 4 April 2019
Accepted: 5 June 2019
First Online: 13 July 2019
Duality of interest
: MO, TO, TT and TW report no conflicts of interest. MJ reports receiving grant support from the NHMRC of Australia (Project Grant: 1148060) and unrestricted grant support from VentureWise (a wholly owned commercial subsidiary of NPS MedicineWise) to conduct a commissioned project funded by AstraZeneca. MEC received consulting fees from Merck, GlaxoSmithKline, Amgen and AstraZeneca, and lecture fees from Servier. SaH reports personal fees and non-financial support from AstraZeneca, Bristol-Myers Squibb, Janssen, MSD and Sanofi, and personal fees from Abbott, Boehringer Ingelheim, Eli Lilly and Company, Novartis, Novo Nordisk, Servier and Takeda. PH received consulting fees from Servier. StH reports lecture fees from Servier, Takeda and Novartis. GM reports personal fees from Servier, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Novartis, Menarini Group, Recordati and Takeda Pharmaceutical Company. MM received personal fees from Novo Nordisk, Sanofi, Eli Lilly and Company, Merck Sharp & Dohme, Abbott, Novartis, Servier and AstraZeneca, and grant support from Novo Nordisk, Sanofi, Eli Lilly and Company, Merck Sharp & Dohme and Novartis. BW received lecture fees from Servier, Novartis, Daiichi Sankyo, Pfizer and Boehringer Ingelheim, and serves on trial steering committees for Novartis, Relypsa and Vascular Dynamics. JC received research grants from the NHMRC of Australia and from Servier for the ADVANCE trial and ADVANCE-ON post-trial follow-up, and honoraria for speaking about these studies at scientific meetings. MW reports consultancy fees from Amgen and Kirin and grant support from the NHMRC. VP reports honoraria for scientific lectures from Boehringer Ingelheim, Merck, AbbVie, Roche, AstraZeneca and Servier, and serves on steering committees and advisory boards supported by AbbVie, Astellas, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen and Pfizer.
